Iron in Health and Disease: An Update
- 259 Downloads
Iron is an essential micronutrient for oxygen transport, cellular energy metabolism, and many enzymatic reactions. Complex physiological processes have evolved for iron acquisition to meet metabolic needs while avoiding toxicity from iron-generated free radicals. Systemic iron homeostasis is centered around the regulation of iron absorption from duodenum and iron release from stores by hepcidin. Intracellular iron is maintained under tight control by iron regulatory proteins acting at post-transcriptional level. Despite these elaborate mechanisms, iron status is frequently altered by environmental or genetic influences. Iron deficiency anemia is the most common nutritional disorder affecting a quarter of the world population. Iron deficiency is associated with impaired cognitive development and reduced capacity for physical work, making it a high priority for public health initiatives. Chronic inflammation from infections or other causes limits iron availability and contributes to anemia of chronic disease. At the opposite end are conditions where iron overload leads to serious complications from organ damage. Mutations in HFE gene are the most frequent cause of hereditary hemochromatosis in European population, but rare elsewhere in the world. Iron overload develops in dyserythropoietic anemias from increased intestinal absorption. Transfusional iron overload, most often observed in thalassemia, is increasing among cancer survivors due to the use of protocols requiring intensive transfusion support. Tissue-specific brain iron overload is observed in some degenerative neurological diseases without an increase in systemic iron. New insights into iron metabolism are guiding the development of novel therapies for iron deficiency and iron overload.
KeywordsIron Hemochromatosis Anemia Hepcidin
Compliance with Ethical Standards
Conflict of Interest
- 1.Anderson GJ, Vulpe CD. The cellular physiology of iron. In: Yehuda S, Mostofsky DI, editors. Iron Deficiency and Overload [Internet]. Totowa: Humana Press; 2009. p. 3–29. Available at: http://www.springerlink.com/content/t06688vw15j12666. Accessed 20 Oct 2011.
- 2.Silva B, Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta. 1852;2015:1347–59.Google Scholar
- 3.Wang C–Y, Babitt JL. Liver iron sensing and body iron homeostasis. Blood. 2019;133:18–29.Google Scholar
- 5.Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 1823;2012:1434–43.Google Scholar
- 6.Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–3.Google Scholar
- 9.Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271–6.Google Scholar
- 12.Anderson CP, Shen M, Eisenstein RS, Leibold EA. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta. 1823;2012:1468–83.Google Scholar
- 15.Lewis SM, Emmanuel JC. Global concept of iron deficiency. In: Yehuda S, Mostofsky DI, editors. Iron Deficiency and Overload [Internet]. Totowa: Humana Press; 2009. p. 299–312. Available at: http://www.springerlink.com/content/l6725130772v362t/. Accessed 20 Oct 2011.
- 16.Alvarez–Uria G, Naik PK, Midde M, Yalla PS, Pakam R. Prevalence and severity of anaemia stratified by age and gender in rural India [Internet]. Anemia. 2014. Available at: http://www.hindawi.com/journals/anemia/2014/176182/abs/. Accessed 7 July 2019.
- 18.NFHS-4 National Report [Internet]. Available at: http://rchiips.org/nfhs/NFHS-4Reports/India.pdf. Accessed 7 July 2019.
- 22.Neuberger A, Okebe J, Yahav D, Paul M. Oral iron supplements for children in malaria-endemic areas. Cochrane Database of Systematic Reviews [Internet]. 2016. Available at: http://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006589.pub4/abstract. Accessed 7 July 2019.
- 23.Paganini D, Uyoga MA, Kortman GAM, et al. Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomised controlled study in Kenyan infants. Gut. 2017;66:1956–67.Google Scholar
- 25.Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113:5277–86.Google Scholar
- 27.Nai A, Pagani A, Silvestri L, et al. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood. 2011;118:4459–62.Google Scholar
- 32.Sandhu K, Flintoff K, Chatfield MD, et al. Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease. Blood. 2018;132:101–10.Google Scholar
- 33.Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload–related disease in HFE hereditary hemochromatosis. New Engl J Med. 2008;358:221–30.Google Scholar
- 34.Lok CY, Merryweather-Clarke AT, Viprakasit V, et al. Iron overload in the Asian community. Blood. 2009;114:20–5.Google Scholar
- 35.Colah RB, Gorakshakar A. Control of thalassemia in India. Thalassemia Reports [Internet]. 2014;4. Available at: http://www.pagepressjournals.org/index.php/thal/article/view/thal.2014.1955. Accessed 30 Sep 2014.
- 36.Ganz T, Jung G, Naeim A, et al. Immunoassay for human serum erythroferrone. Blood. 2017;130:1243–6.Google Scholar
- 41.Chiang S, Kovacevic Z, Sahni S, et al. Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich’s ataxia. Clin Sci. 2016;130:853–70.Google Scholar
- 42.Hayflick SJ, Kurian MA, Hogarth P. Neurodegeneration with brain iron accumulation. In: Geschwind DH, Paulson HL, Klein C, editors. Handbook of Clinical Neurology [Internet]: Elsevier; 2018. p. 293–305. Available at: http://www.sciencedirect.com/science/article/pii/B9780444632333000191. Accessed 7 July 2019.
- 43.Klopstock T, Tricta F, Neumayr L, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol. 2019;18:631–42.Google Scholar